Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis

Inclusion Criteria: * Patient aged of 18 years or older, * Patients with relapsing granulomatosis with polyangiitis positive for PR3-ANCA at inclusion according to the ACR/EULAR 2022 classification criteria, and/or the 2012 revised Chapel Hill Consensus Conference definition. * Patients with an active disease defined as a Birmingham Vasculitis Activity Score (BVAS) ≥ 3, * Patients within the first 21 days following initiation/increase of glucocorticoids at a dose ≤1 mg/kg/day (pulses of methylprednisolone before oral glucocorticoid therapy are authorized) * Patient able to give written informed consent prior to participation in the study, - Affiliation with a mode of social security (profit or being entitled). Exclusion Criteria * Patients with MPO-positive AAV, or other vasculitis, defined by the ACR criteria and/or the Chapel Hill Consensus Conference, * Patients with vasculitis in remission of the disease defined as a BVAS \< 3, * Patients with a newly-diagnosis of GPA * Patients treated with rituximab within the last 6 months before inclusion * Patients treated with cyclophosphamide within the last 6 months before inclusion * Patients with severe cardiac failure defined as class IV in New York Heart Association * Subject known to be seropositive for human immunodeficiency virus (HIV), hepatitis B (included history of previous infection) or hepatitis C * Patients with active cancer or recent cancer (\< 5 years), except basocellular carcinoma and prostatic cancer of low …